NEW YORK ( TheStreet) -- Shares of Pharmaceutical Product Development (Nasdaq: PPDI) have taken a tremendous swing upward. The stock is trading at $32.22 as of 10:06 a.m. ET, 25.6% above Friday's closing price of $25.66. Volume is at 5.7 million, 3.7 times the daily average of 1.5 million. Pharmaceutical Product Development has a market cap of $3 billion and is part of the health care sector and health services industry. Shares are down 5.5% year to date as of the close of trading on Friday. Pharmaceutical Product Development, Inc., a contract research organization, provides drug discovery, development, and lifecycle management services. It operates in two segments, Clinical Development Services and Laboratory Services. The company has a P/E ratio of 41.6, above the average health services industry P/E ratio of 18.2 and above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Pharmaceutical Product Development as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, reasonable valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full Pharmaceutical Product Development Ratings Report. See our top % gaining stocks list for other stocks that are soaring today, or get investment ideas from our investment research center. Interested in other stocks that are soaring? Get free SMS text alerts sent to you when the action happens by texting SOAR to 95370 or select from multiple alert options.
More from Markets
Replay: Jim Cramer's Thoughts on Earnings, Apple, and Snap
Jim Cramer has some advice for investors listening to their market gurus, and he weighs in on how markets are doing with the slew of earnings that we've received and what he thinks of the reported offer Apple made Intel for its smartphone modem chip business.
IMF Slashes Global Growth Forecast in Strange Win for Trump's Economy
The International Monetary Fund cut its forecast for global growth this year to 3.2%, from an April projection of 3.3%. But the organization increased its forecast for U.S. growth by a 0.3 percentage point to 2.6%.
Don't Fret an Earnings Recession and Keep an Eye on These Market Catalysts
Worried about an earnings recession? Don't be. Invesco's Kristina Hooper sits down with TheStreet to break down the market catalysts she's watching, why she isn't worried about an earnings recession and she's got some advice for oil investors.
FREE WEBINAR: How to Invest in the Coming Fintech Revolution
TheStreet's Stephen 'Sarge' Guilfoyle hosts a free half-hour Webinar with top experts on how to make money in the emerging field of fintech and digital payments.